Related Experiment Video

Updated: May 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A Patient Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of

Eric B Lynam1, Jiin Leaw, Matthew B Wiener

  • 1Pharmatech Oncology, Inc., 789 Sherman Street, Suite 600, Denver, Colorado 80203.

Drug Information Journal
|August 31, 2013
PubMed

Insights

Just-In-Time (JIT) clinical trial enrollment methods significantly increased patient participation compared to traditional approaches. This patient-focused strategy accelerates trial completion and improves administrative efficiency in cancer research.

Area of Science:

  • Oncology
  • Clinical Research Methodology
  • Health Services Research

Background:

  • Adult cancer patient participation in US clinical trials has stagnated around 3% for decades.
  • Traditional research models limit patient access through fixed, predetermined sites, hindering trial completion rates.

Purpose of the Study:

  • To compare the enrollment outcomes of traditional clinical trial methodologies with a patient-focused approach.
  • To evaluate the effectiveness of the Just-In-Time (JIT) research methodology in increasing patient participation and trial efficiency.

Main Methods:

  • A patient-prioritized Just-In-Time (JIT) research method was implemented concurrently with traditional research sites across three cancer trials.
  • JIT research sites were activated after candidate patients were identified, contrasting with traditional sites activated in advance.

Main Results:

  • JIT sites demonstrated enrollment rates equal to or up to 2.75 times greater than traditional sites.
  • The average number of patients enrolled per site was comparable between JIT (1.82) and traditional (1.78) methods.
  • Fewer JIT sites failed to enroll any patients (7%) compared to traditional sites (37%).

Conclusions:

  • The Just-In-Time (JIT) methodology shows significant promise for enhancing cancer clinical trial enrollment.
  • JIT represents a viable solution to improve the efficiency of clinical trial administrative activities and accelerate research.
  • This patient-focused approach ethically increases participation and supports faster trial completion.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...